Payment overview · 2025
General Payments
$968.25
38 reported records · 11 companies
Healthcare provider profile · identity verified
Lev S. Simkhayev, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EAST BRUNSWICK, NJ · NPI 1578563243
Verified facts
What the public records show
CMS Open Payments records show Lev S. Simkhayev, M.D. received $968.25 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Rexulti, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $403.39 | 41.7% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $261.20 | 27.0% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.59 | 16.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.13 | 3.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.87 | 1.9% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $16.24 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.23 | 1.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.46 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.67 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.67 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.80 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $968.25 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $261.20 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $154.58 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.37 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $124.35 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.22 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 70 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 259 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
259 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 79 |
| Losartan Potassium | Losartan Potassium | 303 | 69 |
| Furosemide | Furosemide | 293 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 65 |
| Gabapentin | Gabapentin | 270 | 65 |
| Eliquis | Apixaban | 259 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 53 |
| Potassium Chloride | Potassium Chloride | 215 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 48 |
| Metformin Hcl | Metformin Hcl | 199 | 55 |
| Mirtazapine | Mirtazapine | 189 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 35 |
| Omeprazole | Omeprazole | 154 | 33 |
| Allopurinol | Allopurinol | 149 | 43 |
| Xarelto | Rivaroxaban | 147 | 22 |
| Simvastatin | Simvastatin | 141 | 30 |
| Famotidine | Famotidine | 131 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 19 |
| Donepezil Hcl | Donepezil Hcl | 118 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 40 |
| Divalproex Sodium | Divalproex Sodium | 115 | 18 |
| Lisinopril | Lisinopril | 112 | 27 |
| Tramadol Hcl | Tramadol Hcl | 112 | 29 |
| Carvedilol | Carvedilol | 111 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 21 |
| Farxiga | Dapagliflozin Propanediol | 96 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 14 |
| Trazodone Hcl | Trazodone Hcl | 92 | 19 |
| Jardiance | Empagliflozin | 91 | 17 |
| Montelukast Sodium | Montelukast Sodium | 87 | 16 |
| Chlorthalidone | Chlorthalidone | 86 | 27 |
| Memantine Hcl | Memantine Hcl | 86 | 18 |
| Alprazolam | Alprazolam | 81 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 33 |
| Levetiracetam | Levetiracetam | 73 | suppressed |
| Spironolactone | Spironolactone | 71 | 19 |
| Creon | Lipase/Protease/Amylase | 70 | 23 |
| Propranolol Hcl | Propranolol Hcl | 69 | 17 |
| Lactulose | Lactulose | 68 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Valsartan | Valsartan | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 63 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 61 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 19 |
| Folic Acid | Folic Acid | 59 | 14 |
| Ibuprofen | Ibuprofen | 55 | 18 |
| Ozempic | Semaglutide | 55 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 17 |
| Midodrine Hcl | Midodrine Hcl | 52 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Azithromycin | Azithromycin | 48 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 19 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Risperidone | Risperidone | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 13 |
| Nystatin | Nystatin | 43 | 18 |
| Repaglinide | Repaglinide | 43 | 12 |
| Finasteride | Finasteride | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Febuxostat | Febuxostat | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Linzess | Linaclotide | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 33 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Austedo | Deutetrabenazine | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Glimepiride | Glimepiride | 30 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 12 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 27 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nystop | Nystatin | 26 | 16 |
| Dexamethasone | Dexamethasone | 25 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 24 | suppressed |
| Nyamyc | Nystatin | 24 | 16 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $968.25 · 38 records | ABBVIE INC. | AIRSUPRA, CREON, CRYSVITA, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VRAYLAR, XIFAXAN, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error